NRXP NRX Pharmaceuticals, Inc.: institutional ownership and insider trading
50 funds reported holding $52.2M of NRX Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net bought $23.3M, with 17 new positions and 5 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
Famous investors holding NRXP
- Ken Griffin (Citadel Advisors): $3.81M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $158K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $108K, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $50.3K, 0.0% of the portfolio
Largest institutional holders of NRXP
- B Group, Inc. — $16.7M
- VANGUARD CAPITAL MANAGEMENT LLC — $6.62M
- CITADEL ADVISORS LLC — $3.81M
- AMERIPRISE FINANCIAL INC (AMP) — $3.80M
- BALYASNY ASSET MANAGEMENT L.P. — $3.66M
- AdvisorShares Investments LLC — $2.70M
- VANGUARD GROUP INC — $1.98M
- COMMONWEALTH EQUITY SERVICES, LLC — $1.86M
- UBS Group AG (UBS) — $1.73M
- GEODE CAPITAL MANAGEMENT, LLC — $1.29M
Recent NRXP insider trades
- Dec 17, 2024: Javitt Jonathan C bought 40,000 shares ($46.8K)
5%+ owners
- The B Group, Inc.: 12.6% (Schedule 13G, filed Aug 21, 2025)